Results 221 to 230 of about 19,582 (256)

[Pharmacotherapy in HFrEF].

Deutsche medizinische Wochenschrift (1946), 2021
Since publication of the European Society guidelines for the diagnosis and treatment of acute and chronic heart failure in 2016, numerous studies provided new evidence how to further optimize heart failure therapy.Besides recent device-based therapeutic options, promising new drug developments give a glimmer of hope that the prognosis of this ...
Gülmisal, Güder, Stefan, Frantz
openaire   +1 more source

HFrEF phenotyping in real life

European Heart Journal, 2023
Abstract Background In May 2021 an HFA position paper[1] by Rosano GMC et al. classified patients with heart failure with reduced ejection fraction (HFrEF) into 11 phenotypes based on blood pressure, heart rate, renal function, potassium level and rhythm and assigned them to different prescription ...
A Weidenhammer, S Prausmueller, N Panagiotides, H Arfsten, G Heitzinger, G Spinka, A Barkhudaryan, P Bartko, M Huelsmann, N Pavo   +9 more
openaire   +1 more source

Metabolomic Profile in HFpEF vs HFrEF Patients

Journal of Cardiac Failure, 2020
Heart failure with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) are associated with metabolic derangements, which may have different pathophysiological implications.In new-onset HFpEF (EF of ≥50%, n = 46) and HFrEF (EF of
Camilla Hage, Lars Löfgren, Filippos Michopoulos, Ralph nilsson, Pia Davidsson, Chanchal Kumar, Mattias Ekström, Maria J. Eriksson, Patrik Lyngå, Bengt Persson, Hakan Wallén, Li Ming Gan, Hans Persson, Cecilia Linde   +13 more
openaire   +2 more sources

Skeletal muscle alterations in HFrEF vs. HFpEF

Current Heart Failure Reports, 2017
Severe exercise intolerance and early fatigue are hallmarks of heart failure patients either with a reduced (HFrEF) or a still preserved (HFpEF) ejection fraction. This review, therefore, will provide a contemporary summary of the alterations currently known to occur in the skeletal muscles of both HFrEF and HFpEF, and provide some further directions ...
Volker, Adams, Axel, Linke, Ephraim, Winzer   +2 more
openaire   +2 more sources

HFrEF pharmacological treatment: ivabradine

2018
Ivabradine slows down the heart rate through a blockade of the funny current channels in the sinoatrial node cells. The efficacy of the drug was tested in a large outcome clinical trial in stable chronic heart failure with reduced ejection fraction, in sinus rhythm, on a contemporary background therapy including beta blockers.
openaire   +2 more sources

Vericiguat in HFrEF

JACC: Heart Failure, 2023
openaire   +1 more source

Neue Therapiekonzepte der HfrEF

Kardiologie up2date, 2021
Amr Abdin, Jan Wintrich, Michael Böhm
openaire   +1 more source

Co-morbidity (HFrEF and HFpEF): hypertension

2018
Hypertensive heart disease is a major cause of heart failure (HF) and mortality. Hypertension precedes HF occurrence in 75% of cases, and carries a sixfold increase in HF risk as compared to non-hypertensive individuals. Most importantly, a minority of patients survive 5 years after the onset of hypertensive HF.
Francesco Paneni, Massimo Volpe
openaire   +2 more sources

Comparison Chart: Some Drugs for HFrEF

The Medical Letter on Drugs and Therapeutics
Comparison Chart: Some Drugs for ...
openaire   +2 more sources

HFrEF pharmacological treatment: beta blockers

2018
By incremental steps over several decades of research, beta blockers have evolved ‘from bench to bedside’, emerging as a keystone of modern optimal pharmacotherapy for heart failure. This chapter starts by detailing the story of their development, focusing on the randomized trials that established their clinical efficacy in reducing hospitalization and
openaire   +1 more source